Literature DB >> 16469755

The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours.

K Last1, L Maharaj, J Perry, S Strauss, J Fitzgibbon, T A Lister, S Joel.   

Abstract

BACKGROUND: Diffuse large B-cell lymphoma patients with low serum selenium concentration at presentation have a lower response rate and overall survival than patients with higher serum selenium. The co-administration of selenium with conventional chemotherapy may be useful in these patients. PATIENTS AND METHODS: We investigated the activity of two selenium species, methylseleninic acid (MSA) and selenodiglutathione (SDG) in a panel of human lymphoma cell lines and in a primary lymphoma culture system.
RESULTS: Both compounds demonstrated cytostatic and cytotoxic activity with EC(50) values in the range 1.0-10.2 microM. Cell death was associated with an increase in the sub-G1 (apoptotic) fraction by flow cytometry and was not preceded by any obvious cell cycle arrest. SDG, but not MSA, resulted in marked increases in intracellular ROS, particularly in CRL2261 and SUD4 cells in which the cytotoxic activity of SDG was partly, or completely, inhibited by n-acetyl cysteine, suggesting a dependence on ROS for activity in some cells. Both MSA and SDG showed a concentration dependent reduction in percentage viability after a 2-day exposure in primary lymphoma cultures, with EC(50) values in the range 39-300 microM and 9-28 microM, respectively.
CONCLUSION: The selenium compounds MSA and SDG induce cell death in lymphoma cell lines and primary lymphoma cultures, which with SDG may be partly attributable to the generation of ROS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469755     DOI: 10.1093/annonc/mdl004

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

1.  Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells.

Authors:  Nong Xiang; Rui Zhao; Weixiong Zhong
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-01       Impact factor: 3.333

2.  Differential acute effects of selenomethionine and sodium selenite on the severity of colitis.

Authors:  Franziska Hiller; Lisa Oldorff; Karolin Besselt; Anna Patricia Kipp
Journal:  Nutrients       Date:  2015-04-10       Impact factor: 5.717

3.  Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway.

Authors:  Feifei Wu; Wei Cao; Huaping Xu; Mingxia Zhu; Jing Wang; Xiaoyan Ke
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

Review 4.  Therapeutic Benefits of Selenium in Hematological Malignancies.

Authors:  Melanie A Ehudin; Upendarrao Golla; Devnah Trivedi; Shobha D Potlakayala; Sairam V Rudrabhatla; Dhimant Desai; Sinisa Dovat; David Claxton; Arati Sharma
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

5.  Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial.

Authors:  Ralph Muecke; Oliver Micke; Lutz Schomburg; Jens Buentzel; Michael Glatzel; Dieter Baaske; Regina Berndt-Skorka; Franz J Prott; Berthold Reichl; Klaus Kisters; Ulrich Schaefer; Jutta Huebner; Hans Th Eich; Guenther Kundt; Irenaeus A Adamietz
Journal:  Radiat Oncol       Date:  2013-03-25       Impact factor: 3.481

Review 6.  Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance?

Authors:  Caroline R B Rocourt; Wen-Hsing Cheng
Journal:  Nutrients       Date:  2013-04-19       Impact factor: 5.717

Review 7.  Selenium and selenoproteins: it's role in regulation of inflammation.

Authors:  Sneha Hariharan; Selvakumar Dharmaraj
Journal:  Inflammopharmacology       Date:  2020-03-06       Impact factor: 4.473

Review 8.  Selenium in oncology: from chemistry to clinics.

Authors:  Oliver Micke; Lutz Schomburg; Jens Buentzel; Klaus Kisters; Ralph Muecke
Journal:  Molecules       Date:  2009-10-12       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.